News & Resources

Telephone Visits Bridge the Gap to Vulnerable Populations

Since the outbreak of COVID-19, telehealth has emerged as a way to continue patient care while minimizing risk of virus exposure. Interestingly, telehealth visits are not always on a screen. Many patients—particularly those who are older or have lower incomes—prefer to communicate with their providers via telephone over video visits. When parts of the US first went into lockdown, 2 clinics reported that as many as 50% to 75% of patient visits were handled by telephone. The Centers for Medicare & Medicaid Services stated that nearly a third of patients who received telehealth services in Spring 2020 did so using audio-only telephone calls. In tribal communities, telephone visits composed about 80% of virtual visits.

While not without limitations, this approach has some distinct benefits, as described by Mary Chris Jaklevic, MSJ, in a 2020 JAMA Medical News & Perspectives article. For example, telephone visits enable ongoing communication with vulnerable populations who may struggle with technology or who have responsibilities that interfere with their ability to have a video or in-person visit. These populations include the 13% of US residents who do not have high-speed internet, and as many as 25% of Medicare beneficiaries who lack a smartphone or a computer with broadband access. These percentages are higher among low-income, Black, and Hispanic beneficiaries and among those with disabilities.

Many practices continue to rely on the telephone to provide a range of services that were once handled face-to-face. These visits may offer an effective way to triage patients; physicians can take medical histories, order or follow up on lab and imaging tests over the phone, and decide whether an in-person visit is needed. Telephone visits can also help physicians monitor patients with chronic conditions, such as cardiovascular disease, hypercholesterolemia, and some hematologic conditions. From the patients’ perspective, some people prefer the privacy that telephone visits afford, and many value the convenience and the safety of avoiding close contact.

Some US payors and physician groups are advocating for continued use of telephone visits even after COVID-19 restrictions are lifted. At least 2 US states have passed legislation for Medicaid coverage of telephone visits after the pandemic.

One limitation of telephone visits is that communicating by phone doesn’t allow a physician to observe a patient’s nonverbal cues, which are sometimes vital to reading a patient’s emotions, gauging whether they understand the information being discussed, and building rapport. It also removes the “human touch,” and is inappropriate when delivering devastating news to patients and their families. Therefore, decisions on the appropriateness of this care model will need to be patient-specific and based on individual circumstances.

High level: Physician organizations seeking continued reimbursement for telehealth visits post-pandemic will need to be able to provide data on the improvements in quality, cost-effectiveness, and access that they afford. For example, it will be interesting to learn whether remote visits for patients with chronic conditions affect hospitalizations or emergency department visits. Now that many patients have become accustomed to telehealth visits, payors should consider the impact and potential backlash of removing those services after the pandemic.

Ground level: For patients with chronic conditions or other health issues, a hybrid arrangement that includes both in-person and telephone visits may be a useful approach. This enables continuity of patient care while supporting the provider-patient relationship and showing patients that their time and resources are respected.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.